Study sheds light on angiogenesis inhibitors, points to limitations, solutions

March 03, 2009

A new generation of cancer drugs designed to starve tumors of their blood supply - called "angiogenesis inhibitors"-succeeds at first, but then promotes more invasive cancer growth-sometimes with a higher incidence of metastases, according to a new study in animals. The research clarifies similar findings in other animal studies and is consistent with some early evidence from a small number of clinical trials with cancer patients.

"People have thought that angiogenesis-inhibiting therapy should hinder metastasis, but these studies show this is not necessarily the case," says Gabriele Bergers, PhD, co-author of a paper reporting the study in the March 3, 2009 issue of the journal "Cancer Cell." Bergers is an associate professor of neurosurgery and anatomy at the University of California, San Francisco (UCSF).

The scientists urge new studies to determine if the drugs affect tumors in patients as they do in their mouse models of human cancers. They call for preclinical and clinical trials combining angiogenesis-inhibiting drugs with ones targeting the capability for invasion and metastasis. Some treatment strategies already in clinical trials that pair angiogenesis inhibitor drugs with chemotherapy, for example, might gain the first drug's early benefit without triggering subsequent invasion or metastasis, they note.

"The ability of angiogenesis inhibitors to starve tumors rather than poison them has been a true breakthrough," says Douglas Hanahan, PhD, professor of biochemistry and biophysics at UCSF and co-senior author on the paper. "But they are not likely to be a one-stop fix. No cancer drug has yet been found to cure most forms of human cancer. Therapies beat it back, but almost inevitably the cancer develops some form of resistance."

Hanahan and Bergers are both scientists at the UCSF Helen Diller Family Comprehensive Cancer Center.

The other co-senior author of the paper is Oriol Casanovas, PhD , a group leader at the Catalan Institute of Oncology-IDIBELL, in Spain.

In addition to their call for more studies of angiogenesis inhibitors' effects, the researchers encourage more research to identify the mechanisms underlying cancer's resurgence after initial success with the angiogenesis inhibitors. They suspect that the increased invasion and/or metastasis is the tumor's response to starvation induced by the drugs.

"A well vascularized tumor is well fed and happy," Hanahan says. "It has no driving force to become more invasive. We hypothesize from the mouse models that if you cut off the tumor's blood supply this drives the cancer to become more invasive-more metastatic- as it seeks more oxygen and nutrients."

The "Cancer Cell" paper extends earlier findings reported by Casanaovas, Hanahan and Bergers in 2005 and 2008 (Casanovas O. et al. Cancer Cell 2005; Du R. et al. Cancer Cell 2008), and it appears along with one by another research team from Robert Kerbel and colleagues at the University of Toronto, also reporting evidence of increased metastasis in mice treated with anti-angiogenesis drugs. In August, 2008, Bergers and Hanahan reviewed all of the recent research addressing resistance to angiogenesis inhibitor therapy in the journal "Nature Reviews Cancer."

The scientists tested the effects of the anti-angiogenic drug sunitinib (manufactured as Sutent) in mouse models of both pancreatic neuroendocrine cancer and glioblastoma, the most common type of primary brain tumor. In both cancers, they found that treated tumors shrank or stabilized but did not disappear during the first weeks of treatment. But after this initial benefit, they detected an adaptive response by the tumor. The glioblastomas increased invasion into adjacent normal tissue. The pancreatic tumors also became more invasive and, in addition, metastasized to the liver.

"Our animal studies are consistent with some clinical results that human glioblastomas adapt to the angiogenesis-inhibiting drugs," Bergers says. "Scientists have reported results from a clinical trial in which a subset of patients developed tumor recurrence at many sites during the course of treatment with bevacizumab, an angiogenesis inhibitor. The recurrence was measured by MRI imaging."

"While anti-angiogenesis drugs are in general not proving to be an enduring success, this does not mean they aren't valuable therapies," she adds. "There is growing evidence that the drugs improve the quality of life, or even provide increased survival - typically of a few months for glioblastoma patients. The drugs also can reduce edema in brain tumors and in some instances restore memory and speech."

A tumor's resistance to angiogenesis inhibitors differs from resistance to chemotherapy drugs, Bergers explains. The targets of anti-angiogenic therapy are normal cells that form the tubes of blood vessels, known as endothelial cells. Despite the fact that the drugs are still effective against these cells, resistance develops because the tumor finds additional pathways to circumvent the drug's inhibitory effect. One evasive tumor strategy involves tapping growth factors in the body other than VEGF for the new blood vessel growth they need. If the tumor can't rebuild its vasculature to a sufficient level, it can adopt another strategy-to spread and become invasive.

In contrast, tumor cells resist chemotherapy by cell-intrinsic mechanisms such as mutating the gene targeted by the drug, or changing how the tumor takes up or expels the drug.

One class of anti-angiogenesis drugs works by blocking the action of an essential protein known as vascular endothelial growth factor, or VEGF, which normally stimulates new blood vessel growth. The strategy of starving tumors by depriving them of nutrients and oxygen in blood was first proposed in the early 1970s by the late Dr. Judah Folkman at Harvard Medical School. The idea took more than two decades to gain traction in the research and clinical oncology communities, but it gained acceptance as new research confirmed its promise. Clinical trials are now the focus of great interest and hope.

Clinical trials with anti-VEGF drugs have had mixed results. One trial, using the anti-VEGF drug bevacizumab in metastatic breast cancer failed, and a recent trial, also in breast cancer did not increase survival, Hanahan and Bergers say. The sobering results from animal studies may explain why.

Lead authors on the paper are Marta Paez-Ribes, a graduate student at the Catalan Institute of Oncology-IDIBELL; and Elizabeth Allen, PhD, a UCSF staff scientist in the Hanahan laboratory at UCSF.

Other co-authors are James Hudock in neurosurgery at UCSF; Takaaki Takeda, Hiroaki Okuyama and Masahiro Inoue, all of Osaka Medical Center for Cancer and Cardiovascular Disease; and Francesc Viñals at the Catalan Institute of Oncology-IBIDELL and the University of Barcelona.

Research support included the National Cancer institute in the U.S., and MICINN and AGAUR in Spain.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care. For further information, visit http://www.ucsf.edu.

The University of California, San Francisco

---

---

	Retinal and Choroidal Angiogenesis by John Penn (Editor) Retinal and choroidal angiogenesis are the leading causes of irreversible vision loss in developed countries. For this reason, ocular angiogenesis is an intensely studied process, and the field is advancing at an astounding pace. It has become increasingly difficult to manage the vast amount of information generated by the growing group of interested investigators, thus a resource is needed that distills and summarizes our progress to date. Retinal and Choroidal Angiogenesis provides a comprehensive, in-depth review of our current understanding of the growth of blood vessels within the eye. Renowned academic scientists, pharmaceutical scientists, and clinician-scientists have contributed chapters identifying the cellular and molecular mechanisms of retinal and choroidal angiogenesis;...
	Therapy for Ocular Angiogenesis: Principles and Practice by Arup Das (Author), Thomas Friberg (Author) Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. In addition, retinal and choroidal neovascularization are the major causes of vision loss in this country. With the new era of anti-angiogenic therapies already in practice, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs. Therapy for Ocular Angiogenesis: Principles and Practice covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular...
	Tumor Angiogenesis and Microcirculation (Basic and Clinical Oncology) by Voest/Damore (Author) Compiling the latest developments in anticancer therapies based on the connection between tumor and capillary growth, Tumor Angiogenesis and Microcirculation presents a comprehensive overview of diverse aspects of angiogenesis-related cancer research. Highlights the role angiogenesis and its inhibitors play in the growth, metastasis, and dormancy of tumors! Facilitating the progress of clinical practice with insights from methodological and scientific results, Tumor Angiogenesis and Microcirculation · summarizes biological principles of angiogenesis and microcirculation, from endothelial cells and pericytes, and extracellular matrix regulation to matrix metalloproteinases (MMPs) and plasmin and plasmin inhibitors · examines proangiogenic factors such as vascular endothelial (VEGF)...
	New Research on Angiogenesis Inhibitors by Elmer T. Skinard (Editor), Mohammed Ali Akhavani (Editor), E. Athanasiou (Editor), Manal Chatila (Editor), Antonio P. Ciardella (Editor) Angiogenesis - the growth of new blood vessels - is an important natural process occurring in the body, both for health and as related to disease. Angiogenesis occurs in the healthy body to help heal wounds and to help to restore blood flow to tissues after injury or insult. In females, Angiogenesis also occurs during the monthly reproductive cycle (to rebuild the uterus lining, to mature the egg during ovulation) and during pregnancy (to build the placenta, the circulation between mother and foetus). The healthy body controls angiogenesis through a series of "on" and "off" switches.The main "on" switches are known as angiogenesis-stimulating growth factors. The main "off switches" are known as angiogenesis inhibitors. When angiogenic growth factors are produced in excess of angiogenesis...
	Angiogenesis Research Progress by Thomas J. Lewis (Editor), James Robinson (Editor) This book is dedicated to new and important research in the field of angiogenesis which is a physiological process involving the growth of new blood vessels from pre-existing vessels. Though there has been some debate over this, vasculogenesis is the term used for spontaneous blood-vessel formation, and intussusception is the term for new blood vessel formation by splitting off existing ones. Angiogenesis is a normal process in growth and development, as well as in wound healing. However, this is also a fundamental step in the transition of tumours from a dormant state to a malignant state.
	Role of Prostate-Specific Antigen (PSA) in Pathological Angiogenesis and Prostate Tumor Growth (Cancer Etiology, Diagnosis and Treatments) by Ravikumar Aalinkeel (Author), Stanley A. Schwartz (Author), B. Bindukumar (Author), Gary J. Smith (Author), Kailash C. Chadha (Author) Prostate specific antigen (PSA) is a serine protease present in an enzymatically inactive form in human serum at a concentration of nanograms/ml; serum PSA (S-PSA) is used widely as a surrogate marker in the diagnosis and management of prostate cancer (CaP). However, the vast majority of PSA produced in the prostate is secreted as active enzyme into the seminal fluid or is sequestered within the prostate tissue microenvironment. This book examines the role of the prostate-specific antigen in prostate tumour growth.
	Gale Encyclopedia of Cancer: Angiogenesis inhibitors by RPh.,BCOP Nancy J. Beaulieu (Author) The article is excerpted from Gale Encyclopedia of Cancer The resource students and researchers will turn to for reliable, up-to-date and clearly written information, the Gale Encyclopedia of Cancer is a comprehensive survey of 120 cancers, cancer drugs, traditional and alternative treatments and diagnostic procedures. The Encyclopedia includes entries covering cancers, cancer drugs, treatments, side effects and diagnostic procedures. Entries typically include the following elements: Causes and Symptoms Definition Description Diagnosis Prevention Resources Risks Special Concerns And more An appendix provides complete contact information for cancer centers, national support groups, government agencies and research groups. Features include anatomical...
	Inhibitors in the pipeline: angiogenesis an attractive new target in RA.(bevacizumab): An article from: Internal Medicine News by Bruce Jancin (Author) This digital document is an article from Internal Medicine News, published by International Medical News Group on April 1, 2004. The length of the article is 562 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Inhibitors in the pipeline: angiogenesis an attractive new target in RA.(bevacizumab) Author: Bruce Jancin Publication: Internal Medicine News (Magazine/Journal) Date: April 1, 2004 Publisher: International Medical News Group Volume: 37 Issue: 7 Page: 90(1) Distributed by Thomson...
	Novartis/Schering AG oral angiogenesis inhibitor PTK/ZK completes enrollment for key Phase III metastatic colorectal cancer trial.: An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2004. The length of the article is 757 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: Novartis/Schering AG oral angiogenesis inhibitor PTK/ZK completes enrollment for key Phase III metastatic colorectal cancer trial. Publication: BIOTECH Patent News (Newsletter) Date: May 1, 2004 Publisher: Biotech Patent News Volume: 18 Issue: 5 Distributed by Thomson...
	AngioGenetics AB and Tumour Biology Centre Freiburg collaborate on the exploration of angiogenesis inhibitors for cancer treatment.: An article from: BIOTECH Patent News by Biotech Patent News (Publisher) This digital document is an article from BIOTECH Patent News, published by Biotech Patent News on May 1, 2004. The length of the article is 2286 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: AngioGenetics AB and Tumour Biology Centre Freiburg collaborate on the exploration of angiogenesis inhibitors for cancer treatment. Publication: BIOTECH Patent News (Newsletter) Date: May 1, 2004 Publisher: Biotech Patent News Volume: 18 Issue: 5 Distributed by Thomson...